Last reviewed · How we verify
NCT06709872: BIOC
A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline from Stage I Invasive Ovarian Cancer
trial in Stage I Ovarian Cancer in 400 participants. Participants enrolled and being followed up; not accepting new ones.
3 September 2029
Quick facts
| Lead sponsor | KU Leuven |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 3 September 2024 |
| Primary completion | 3 September 2029 |
| Estimated completion | 3 September 2029 |
| Sites | 1 location across Belgium |
Conditions studied
- Stage I Ovarian Cancer — all drugs for Stage I Ovarian Cancer →
- Borderline Ovarian Tumors — all drugs for Borderline Ovarian Tumors →
Sponsor
KU Leuven — full company profile →
Who can join
18 and older, female only, with Stage I Ovarian Cancer or Borderline Ovarian Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to improve the diagnosis of ovarian cancer by distinguishing between borderline ovarian tumors (BOT) and stage I invasive ovarian cancer. Other than the traditional diagnostic biomarker CA125, the previous study TRANS-IOTA (translational-international ovarian tumor analysis; S51375/S59207), conducted by similar investigators, pointed at biomarkers like HE4, CA72.4, CA15.3, and CCL11, as potential markers to discriminate BOT from stage I cancer. BIOC is the follow-up study, which will include four additional promising biomarkers to expand the panel to nine. The investigators aim to confirm whether a subpanel of these nine biomarkers has diagnostic value. Such a biomarker signature would enhance the accuracy of distinguishing between BOT and stage I invasive ovarian cancer before surgery, leading to more precise treatment and improved patient outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06709872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stage I Ovarian Cancer
Currently open trials in the same condition.
- NCT04794322 — Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer · recruiting
Other KU Leuven trials
Trials by the same sponsor.
- NCT07508696 — Cerebellar Research in Ultrasound Stimulation · NA · not yet recruiting
- NCT07476716 — Peer-modeled Intervention · NA · not yet recruiting
- NCT07534384 — Automated CPET Interpretation: International Validation Study · not yet recruiting
- NCT07419555 — Belgian Lung Function Study · recruiting
- NCT07295600 — Postprandial Effect of Isocaloric Challenge Meals Enriched With Indigenous Fruits and Vegetables on Glucose Metabolism i · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06709872 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by KU Leuven
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06709872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing